Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals
Accumulate slowly - Even though results are not impressive in Q4 2023.
Elevated PE - Negative
Q4 - Results Negative
Company comments for future :
Accumulate slowly - Even though results are not impressive in Q4 2023.
Elevated PE - Negative
Q4 - Results Negative
Company comments for future :
- Future Plans and Strategies:
Expect 20-30% revenue growth in FY24, potential for 40-50% growth if pricing remains the same
Launching new products on commercial scale in FY24
Anticipate rebound in demand for SDAs
Capex of INR16-17 crores expected for new Agro intermediate product, total capex of INR30-35 crores for the year
Operating leverage to increase in FY25 due to new plant operations and continuous flow chemistry
Revenue growth guidance for FY24 is 20-30%
Electrolyte sales expected to have nearly 100% growth in FY24
Flame retardant revenue expected to be INR40-50 crores this year and INR200 crores next year
Tatva Chintan committed to delivering and improving the market for their products going forward.
Trade active
T1 1700 - DoneTrade active
1750 and aboveTrade active
Trade active
T2 Done - Trail SL
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.